Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

metreleptin 5 mg/placebo; 4) pramlintide 180 mcg/metreleptin 2.5 mg; 5) pramlintide 180 mcg/metreleptin 5 mg; 6) pramlintide 360 mcg/metreleptin 1.25 mg; 7) pramlintide 360 mcg/metreleptin 2.5 mg; or 8) pramlintide 360 mcg/metreleptin 5 mg.

Lifestyle intervention was included throughout study (dietary, exercise and behavioral). Body composition was assessed using DEXA scanning at enrollment and again at study termination. Across all treatment arms, approximately 60% (n=360) of patients were deemed evaluable (subjects who completed at least 24 weeks of treatment on study medication and had no major protocol deviations).

As part of an ongoing extension protocol, study participants may continue on therapy for a total of 52 weeks. Data from this study will be submitted for presentation at a future medical meeting and for publication in a peer-reviewed journal.

About Obesity

Obesity is a chronic disorder that affects millions of people and is linked to increased health risk of several medical conditions including type 2 diabetes, non-alcoholic fatty liver disease, high blood pressure, heart disease, stroke, osteoarthritis, sleep disorders and several types of cancers. According to The Obesity Society, obesity is the second leading cause of preventable death in the United States. The total direct and indirect cost attributed to overweight and obesity health issues exceeds $100 billion in the United States each year. Obesity is also rapidly becoming a major health problem in all industrialized nations and many developing countries.

There are different classes of obesity defined by body mass index, or BMI. Overweight is defined as BMI 25 to 29.9 kg/m2, Obesity Class I is BMI 30 to 34.9 kg/m2, Obesity Class II is BMI 35 to 39.9 kg/m2 and Obesity Class III is BMI 40 kg/m2 or more. Of the over 100 million overweight and obese individuals in the United States, over 80 million have a BMI less t
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Trigemina, Inc., a biopharmaceutical company focused on the ... products, announced today that the company has appointed Shashidhar ... officer. Dr. Kori brings over 30 years of clinical ... focused in the neuroscience and headache space. ... clinical team given his vast experience managing clinical development ...
(Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, the White ... of entrepreneurs from across the United States to talk about their experiences with innovation ... be chosen to be among the attendees. , One of the day’s aims is ...
(Date:8/3/2015)... , August 3, 2015 At ... Portland Hospital waved the shortfall of Jude ... stand normally for the first time.      ... http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective Dorsal ... allowing him to carry out his wish to kick ...
(Date:8/3/2015)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), the pioneer ... today announced that it will host its First Quarter ... August 13, 2015 at 4:30 p.m. Eastern Time. ... of fiscal 2016 first quarter results.  A recorded version ... after the call at the Investor Relations portion of ...
Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2
... FRAZER, Pa., Dec. 6, 2010 Cephalon, Inc. (Nasdaq: ... company,s Chairman and Chief Executive Officer, will not be ... will remain on a medical leave of absence indefinitely.  ... Operating Officer, will continue to perform Dr. Baldino,s day-to-day responsibilities ...
... Dec. 6, 2010 Investigators report no evidence of toxicity ... a gene therapy trial using a vector under development ... College London) to correct the inherited bleeding disorder. ... with low and intermediate doses of the vector expected to ...
... SIGNAL HILL, Calif., Dec. 6, 2010 The medical ... recognized by the U.S. Department of Health and Human ... therapeutic discovery."  The designation earns the company a grant ... Project designation and grant is provided for under the ...
Cached Biology Technology:Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely 2Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 2Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 3Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B 4Integrated Medical Systems' Technology Recognized as Qualified Therapeutic Discovery 2
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... GSA BULLETIN science published online 9-20 March includes ... the Southern Pyrenees, and the western Gulf of Mexico. ... in south-central Chile, characterizing the source and age of ... pieces of mid-oceanic ridge found above ground, and large ...
... associated with storing nuclear waste and the possibility of ... may no longer be obstacles on the road to ... the University of Notre Dame, led by Thomas E. ... concurrent professor of chemistry and biochemistry, showcases Notre Dame ...
... WASHINGTON The water flowing through Venice,s famous canals ... not only because of a rising sea level. Although previous ... that the historic city continues to slowly sink, and even ... be continuing to subside, at a rate of about 2 ...
Cached Biology News:How old are these rocks, how were they made, and how long ago did these geologic changes happen? 2How old are these rocks, how were they made, and how long ago did these geologic changes happen? 3How old are these rocks, how were they made, and how long ago did these geologic changes happen? 4How old are these rocks, how were they made, and how long ago did these geologic changes happen? 5How old are these rocks, how were they made, and how long ago did these geologic changes happen? 6How old are these rocks, how were they made, and how long ago did these geologic changes happen? 7New paper by Notre Dame researchers describes method for cleaning up nuclear waste 2AGU: Venice hasn't stopped sinking after all 2AGU: Venice hasn't stopped sinking after all 3AGU: Venice hasn't stopped sinking after all 4
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
... 100-240 V, uses multiplex suspension array technology ... up to 100 proteins and peptides in ... is composed of up to 100 color-coded ... conjugated with a unique reactant specific to ...
Biology Products: